Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-β signaling in a murine colitis model

Biochemical Pharmacology

Volumn 117, Issue , 2016, Pages 57-67

  Li, Guanwei ^a   Ren, Jianan ^a   Hu, Qiongyuan ^a,b   Deng, Youming ^a   Chen, Guopu ^a   Guo, Kun ^a   Li, Ranran ^a   Li, Yuan ^a   Wu, Lei ^a   Wang, Gefei ^a   Gu, Guosheng ^a   Li, Jieshou ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

Antifibrotic therapy; Inflammatory bowel disease; Intestinal fibrosis; Pirfenidone

Indexed keywords

COLLAGEN; COLLAGEN 1A2; COLLAGEN 3A1; DEXTRAN SULFATE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PIRFENIDONE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; GASTROINTESTINAL AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CLINICAL EVALUATION; COLITIS; COLON LENGTH; CONTROLLED STUDY; DIGESTIVE TRACT PARAMETERS; DISEASE ACTIVITY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; FIBROBLAST; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; INTESTINAL FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; PRIORITY JOURNAL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CELL SURVIVAL; COLON; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GERMFREE ANIMAL; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; RANDOMIZATION; RECTAL DRUG ADMINISTRATION; SECRETION (PROCESS); SIGNAL TRANSDUCTION;

ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; COLITIS; COLLAGEN; COLON; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; MICE, INBRED C57BL; PYRIDONES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; SPECIFIC PATHOGEN-FREE ORGANISMS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84981718817     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2016.08.002     Document Type: Article

References (37)

1. [1] Cosnes, J., Cattan, S., Blain, A., Beaugerie, L., Carbonnel, F., Parc, R., Gendre, J.P., Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8:4 (2002), 244–250.
2. [2] Spinelli, A., Correale, C., Szabo, H., Montorsi, M., Intestinal fibrosis in Crohn's disease: medical treatment or surgery?. Curr. Drug Targets 11:2 (2010), 242–248.
3. [3] Olaison, G., Smedh, K., Sjodahl, R., Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 33:3 (1992), 331–335.
4. [4] Louis, E., Collard, A., Oger, A.F., Degroote, E., Aboul Nasr El Yafi, F.A., Belaiche, J., Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 49:6 (2001), 777–782.
5. [5] Zorzi, F., Calabrese, E., Monteleone, G., Pathogenic aspects and therapeutic avenues of intestinal fibrosis in Crohn's disease. Clin. Sci. (Lond.) 129:12 (2015), 1107–1113.
6. [6] Rockey, D.C., Bell, P.D., Hill, J.A., Fibrosis–a common pathway to organ injury and failure. N. Engl. J. Med. 372:12 (2015), 1138–1149.
7. [7] Bettenworth, D., Rieder, F., Medical therapy of stricturing Crohn's disease: what the gut can learn from other organs – a systematic review. Fibrogenesis Tissue Repair, 7(1), 2014, 5.
8. [8] Schaefer, C.J., Ruhrmund, D.W., Pan, L., Seiwert, S.D., Kossen, K., Antifibrotic activities of pirfenidone in animal models. Eur. Respir. Rev. 20:120 (2011), 85–97.
9. [9] Kadir, S.I., Wenzel Kragstrup, T., Dige, A., Kok Jensen, S., Dahlerup, J.F., Kelsen, J., Pirfenidone inhibits the proliferation of fibroblasts from patients with active Crohn's disease. Scand. J. Gastroenterol., 2016, 1–5.
10. [10] Meier, R., Lutz, C., Cosin-Roger, J., Fagagnini, S., Bollmann, G., Hunerwadel, A., Mamie, C., Lang, S., Tchouboukov, A., Weber, F.E., Weber, A., Rogler, G., Hausmann, M., Decreased fibrogenesis after treatment with pirfenidone in a newly developed mouse model of intestinal fibrosis. Inflamm. Bowel Dis. 22:3 (2016), 569–582.
11. [11] Inomata, M., Kamio, K., Azuma, A., Matsuda, K., Kokuho, N., Miura, Y., Hayashi, H., Nei, T., Fujita, K., Saito, Y., Gemma, A., Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir. Res., 15, 2014, 16.
12. [12] Cooper, H.S., Murthy, S.N., Shah, R.S., Sedergran, D.J., Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest. 69:2 (1993), 238–249.
13. [13] Maines, L.W., Fitzpatrick, L.R., French, K.J., Zhuang, Y., Xia, Z., Keller, S.N., Upson, J.J., Smith, C.D., Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase. Dig. Dis. Sci. 53:4 (2008), 997–1012.
14. [14] Yoo, J.H., Ho, S., Tran, D.H., Cheng, M., Bakirtzi, K., Kukota, Y., Ichikawa, R., Su, B., Tran, D.H., Hing, T.C., Chang, I., Shih, D.Q., Issacson, R.E., Gallo, R.L., Fiocchi, C., Pothoulakis, C., Koon, H.W., Anti-fibrogenic effects of the anti-microbial peptide cathelicidin in murine colitis-associated fibrosis. Cell. Mol. Gastroenterol. Hepatol. 1:1 (2015), 55–74, e1.
15. [15] Okayasu, I., Hatakeyama, S., Yamada, M., Ohkusa, T., Inagaki, Y., Nakaya, R., A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98:3 (1990), 694–702.
16. [16] He, W., Dai, C., Key fibrogenic signaling. Curr. Pathobiol. Rep. 3:2 (2015), 183–192.
17. [17] Malgras, B., Pautrat, K., Dray, X., Pasquier, P., Valleur, P., Pocard, M., Soyer, P., Multidisciplinary management of gastrointestinal fibrotic stenosis in Crohn's disease. Dig. Dis. Sci. 60:5 (2015), 1152–1168.
18. [18] King, T.E. Jr., Bradford, W.Z., Castro-Bernardini, S., Fagan, E.A., Glaspole, I., Glassberg, M.K., Gorina, E., Hopkins, P.M., Kardatzke, D., Lancaster, L., Lederer, D.J., Nathan, S.D., Pereira, C.A., Sahn, S.A., Sussman, R., Swigris, J.J., Noble, P.W., Group, A.S., A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370:22 (2014), 2083–2092.
19. [19] Rogler, G., New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?. Dig. Dis. 32 (2014), 39–49.
20. [20] Walker, J.E., Giri, S.N., Margolin, S.B., A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis. Mult. Scler. 11:2 (2005), 149–158.
21. [21] Rodriguez-Castellanos, M., Tlacuilo-Parra, A., Sanchez-Enriquez, S., Velez-Gomez, E., Guevara-Gutierrez, E., Pirfenidone gel in patients with localized scleroderma: a phase II study. Arthritis Res. Ther., 16(6), 2014, 510.
22. [22] Duan, L.J., Qi, J., Huang, T., Gu, X., Xu, D., Kong, X.J., Qian, X.Q., Pirfenidone attenuates bladder fibrosis and mitigates deterioration of bladder function in a rat model of partial bladder outlet obstruction. Mol. Med. Rep., 2015.
23. [23] Simone, N.L., Soule, B.P., Gerber, L., Augustine, E., Smith, S., Altemus, R.M., Mitchell, J.B., Camphausen, K.A., Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study. Radiat. Oncol., 2, 2007, 19.
24. [24] Orozco-Perez, J., Aguirre-Jauregui, O., Salazar-Montes, A.M., Sobrevilla-Navarro, A.A., Lucano-Landeros, M.S., Armendariz-Borunda, J., Pirfenidone prevents rat esophageal stricture formation. J. Surg. Res. 194:2 (2015), 558–564.
25. [25] Dieleman, L.A., Palmen, M.J., Akol, H., Bloemena, E., Pena, A.S., Meuwissen, S.G., Van Rees, E.P., Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114:3 (1998), 385–391.
26. [26] Speca, S., Rousseaux, C., Dubuquoy, C., Rieder, F., Vetuschi, A., Sferra, R., Giusti, I., Bertin, B., Dubuquoy, L., Gaudio, E., Desreumaux, P., Latella, G., Novel PPARgamma modulator GED-0507-34 levo ameliorates inflammation-driven intestinal fibrosis. Inflamm. Bowel Dis., 2015.
27. [27] Koga, H., Yang, H., Adler, J., Zimmermann, E.M., Teitelbaum, D.H., Transanal delivery of angiotensin converting enzyme inhibitor prevents colonic fibrosis in a mouse colitis model: development of a unique mode of treatment. Surgery 144:2 (2008), 259–268.
28. [28] Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., Arimura, A., Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur. J. Pharmacol. 590:1–3 (2008), 400–408.
29. [29] Hirano, A., Kanehiro, A., Ono, K., Ito, W., Yoshida, A., Okada, C., Nakashima, H., Tanimoto, Y., Kataoka, M., Gelfand, E.W., Tanimoto, M., Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge. Am. J. Respir. Cell Mol. Biol. 35:3 (2006), 366–377.
30. [30] Lee, K.W., Everett, T.H.T., Rahmutula, D., Guerra, J.M., Wilson, E., Ding, C., Olgin, J.E., Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation 114:16 (2006), 1703–1712.
31. [31] Meng, J., Zou, Y., Hu, C., Zhu, Y., Peng, Z., Hu, G., Wang, Z., Tao, L., Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway. Shock 38:5 (2012), 567–573.
32. [32] Armendariz-Borunda, J., Lyra-Gonzalez, I., Medina-Preciado, D., Gonzalez-Garcia, I., Martinez-Fong, D., Miranda, R.A., Magana-Castro, R., Pena-Santoyo, P., Garcia-Rocha, S., Bautista, C.A., Godoy, J., Flores-Montana, J., Floresvillar-Mosqueda, J., Armendariz-Vazquez, O., Lucano-Landeros, M.S., Vazquez-Del Mercado, M., Sanchez-Parada, M.G., A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann. Plast. Surg. 68:1 (2012), 22–28.
33. [33] Macias-Barragan, J., Sandoval-Rodriguez, A., Navarro-Partida, J., Armendariz-Borunda, J., The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair, 3, 2010, 16.
34. [34] Conte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., Vancheri, C., Effect of pirfenidone on proliferation, TGF-beta-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur. J. Pharm. Sci. 58 (2014), 13–19.
35. [35] Lin, X., Yu, M., Wu, K., Yuan, H., Zhong, H., Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro. Invest. Ophthalmol. Vis. Sci. 50:8 (2009), 3763–3770.
36. [36] Shi, Q., Liu, X., Bai, Y., Cui, C., Li, J., Li, Y., Hu, S., Wei, Y., In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS One, 6(11), 2011, e28134.
37. [37] Chung, S.A., Jeon, B.K., Choi, Y.H., Back, K.O., Lee, J.B., Kook, K.H., Pirfenidone attenuates the IL-1beta-induced hyaluronic acid increase in orbital fibroblasts from patients with thyroid-associated ophthalmopathy. Invest. Ophthalmol. Vis. Sci. 55:4 (2014), 2276–2283.